{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:36:00Z","timestamp":1740162960885,"version":"3.37.3"},"reference-count":10,"publisher":"American Association for Cancer Research (AACR)","issue":"6","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Summary:<\/jats:title>\n                  <jats:p>In this issue of Cancer Discovery, Pullarkat and colleagues present the results from a phase I clinical trial that is the first to combine small-molecule inhibitors for multiple antiapoptotic proteins, BCL2 as well as BCL-XL, with a traditional chemotherapy backbone for patients with relapsed\/refractory acute lymphoblastic leukemia. This trial has demonstrated impressive response rates with acceptable toxicity while providing proof of concept that dual targeting\u2014hitting BCL2 hard and BCL-XL soft\u2014is both effective and tolerable in a heterogeneous patient population with prior existing cytopenias.<\/jats:p>\n                  <jats:p>See related article by Pullarkat et al., p. 1440.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1158\/2159-8290.cd-21-0261","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T19:10:31Z","timestamp":1622661031000},"page":"1324-1326","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibiting the Inhibitors of Apoptosis: When Two Targets Are Better Than One"],"prefix":"10.1158","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1898-9836","authenticated-orcid":false,"given":"Karilyn T.M.","family":"Larkin","sequence":"first","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, Ohio."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2021,6,2]]},"reference":[{"key":"2022060711084494800_bib1","first-page":"156","article-title":"Treatment of relapsed\/refractory acute lymphoblastic leukemia","volume":"17","author":"Paul","year":"2019","journal-title":"Clin Adv Hematol Oncol"},{"key":"2022060711084494800_bib2","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1007\/s00277-019-03771-2","article-title":"Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)","volume":"98","author":"Giebel","year":"2019","journal-title":"Ann Hematol"},{"key":"2022060711084494800_bib3","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","article-title":"Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity","volume":"11","author":"Wilson","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022060711084494800_bib4","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1182\/bloodadvances.2019001416","article-title":"Cotargeting BCL-2 and MCL-1 in high-risk B-ALL","volume":"4","author":"Moujalled","year":"2020","journal-title":"Blood Adv"},{"key":"2022060711084494800_bib5","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1182\/blood-2007-03-080325","article-title":"Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo","volume":"110","author":"Kang","year":"2007","journal-title":"Blood"},{"key":"2022060711084494800_bib6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"key":"2022060711084494800_bib7","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"key":"2022060711084494800_bib8","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1158\/1078-0432.CCR-14-0259","article-title":"Cell and molecular determinants of in vivo efficacy of the BH3 mimetic ABT-263 against pediatric acute lymphoblastic leukemia xenografts","volume":"20","author":"Suryani","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2022060711084494800_bib9","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"key":"2022060711084494800_bib10","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2016.71.8585","article-title":"Early response\u2013based therapy stratification improves survival in adult early thymic precursor acute lymphoblastic leukemia: a group for research on adult acute lymphoblastic leukemia study","volume":"35","author":"Asnafi","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/6\/1324\/3105072\/1324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/11\/6\/1324\/3105072\/1324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T11:17:41Z","timestamp":1654600661000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/11\/6\/1324\/666578\/Inhibiting-the-Inhibitors-of-Apoptosis-When-Two"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,1]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,2]]},"published-print":{"date-parts":[[2021,6,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-21-0261","relation":{},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"type":"print","value":"2159-8274"},{"type":"electronic","value":"2159-8290"}],"subject":[],"published":{"date-parts":[[2021,6,1]]}}}